

CLAIM AMENDMENTS

The following listing of claims will replace all prior versions and listing of claims in the application.

Claims 1-11 (canceled).

12. (currently amended) A method for preventing reducing the incidence of mortality caused by reoccurrence of cardiovascular events in a patient who has survived a myocardial infarction, the method comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) wherein the content of EPA+DHA in the mixture is greater than 25% by weight and the medicament is administered orally.

13. (previously presented) The method according to claim 12, wherein the content of EPA+DHA in the mixture is from about 30 to about 100% by weight.

14. (previously presented) The method according to claim 12, wherein the content of EPA+DHA in the mixture is about 85% by weight.

Claim 15 (canceled).

16. (previously presented) The method according to claim 14, wherein the medicament is administered orally at a dosage from about 0.7g to about 1.5g daily.

Claim 17 (canceled).

18. (currently amended) A method for preventing reducing the incidence of mortality or sudden death caused by reoccurrence of myocardial infarction in a patient who is a survivor of

myocardial infarction, the method comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), wherein the content of EPA+DHA in the mixture is greater than 25% by weight and the medicament is administered orally.

19. (previously presented) The method according to claim 18, wherein the content of EPA+DHA in the mixture is from about 30 to about 100% by weight.

20. (previously presented) The method according to claim 18, wherein the content of EPA+DHA in the mixture is about 85% by weight.

Claim 21 (canceled).

22. (previously presented) The method according to claim 20, wherein the medicament is administered orally at a dosage from about 0.7g to about 1.5g daily.

Claim 23 (canceled).

24. (currently amended) A method for preventing reducing the incidence of mortality caused by reoccurrence of cardiovascular events in a patient who has survived a myocardial infarction, the method comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids with a content in eicosapentaenoic acid ethyl ester (EPA) or in docosahexaenoic acid ethyl ester (DHA) greater than 25% by weight, wherein the medicament is administered orally.

25. (previously presented) The method according to claim 24, wherein the content of EPA or DHA is from about 60 to about 100% by weight.

Claim 26 (canceled).

27. (currently amended) A method for preventing reducing the incidence of mortality or sudden death caused by the reoccurrence of myocardial infarction in a patient who is a survivor of myocardial infarction, the method comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids with a content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) greater than 25% by weight, wherein the medicament is administered orally.

28. (previously presented) The method according to claim 27, wherein the content of EPA or DHA is from about 60 to about 100% by weight.

Claim 29 (canceled).

30. (previously presented) The method according to claim 16, wherein the content of EPA in the EPA+DHA mixture is from about 40 to about 60% by weight.

31. (currently amended) The method according to claim 16, wherein the content of DHA in the EPA+DHA mixture is from about 25 to about 45% by weight.

32. (currently amended) The method according to claim 16, wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 45% by weight.

33. (previously presented) The method according to claim 22, wherein the content of EPA in the EPA+DHA mixture is from about 40 to about 60% by weight.

34. (currently amended) The method according to claim 22, wherein the content of DHA in the EPA+DHA mixture is from about 25 to about 45% by weight.

35. (currently amended) The method according to claim 22, wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 45% **by weight**.